Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Lysostaphin: model for a specific enzymatic approach to infectious disease.

× No keyword cloud information.

25 in total

1. Antigenic response to topically applied proteins.

Authors: E F Harrison; M E Fuquay; W A Zygmunt
Journal: Infect Immun Date: 1975-02 Impact factor: 3.441

2. epr, which encodes glycylglycine endopeptidase resistance, is homologous to femAB and affects serine content of peptidoglycan cross bridges in Staphylococcus capitis and Staphylococcus aureus.

Authors: M Sugai; T Fujiwara; K Ohta; H Komatsuzawa; M Ohara; H Suginaka
Journal: J Bacteriol Date: 1997-07 Impact factor: 3.490

3. Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus.

Authors: M W Climo; K Ehlert; G L Archer
Journal: Antimicrob Agents Chemother Date: 2001-05 Impact factor: 5.191

4. Gene and protein sequence optimization for high-level production of fully active and aglycosylated lysostaphin in Pichia pastoris.

Authors: Hongliang Zhao; Kristina Blazanovic; Yoonjoo Choi; Chris Bailey-Kellogg; Karl E Griswold
Journal: Appl Environ Microbiol Date: 2014-02-21 Impact factor: 4.792

5. Comparison of four methods for determining lysostaphin susceptibility of various strains of Staphylococcus aureus.

Authors: Caroline M Kusuma; John F Kokai-Kun
Journal: Antimicrob Agents Chemother Date: 2005-08 Impact factor: 5.191

6. Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin.

Authors: R L Patron; M W Climo; B P Goldstein; G L Archer
Journal: Antimicrob Agents Chemother Date: 1999-07 Impact factor: 5.191

7. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis.

Authors: M W Climo; R L Patron; B P Goldstein; G L Archer
Journal: Antimicrob Agents Chemother Date: 1998-06 Impact factor: 5.191

8. Evaluation of Pseudomonas aeruginosa staphylolysin (LasA protease) in the treatment of methicillin-resistant Staphylococcus aureus endophthalmitis in a rat model.

Authors: Irina S Barequet; Zohar Habot-Wilner; Oran Mann; Mary Safrin; Dennis E Ohman; Efrat Kessler; Mordechai Rosner
Journal: Graefes Arch Clin Exp Ophthalmol Date: 2009-03-12 Impact factor: 3.117

9. Pseudomonas aeruginosa LasA protease in treatment of experimental staphylococcal keratitis.

Authors: Irina S Barequet; Guy J Ben Simon; Mary Safrin; Dennis E Ohman; Efrat Kessler
Journal: Antimicrob Agents Chemother Date: 2004-05 Impact factor: 5.191

10. High-level potentiation of lysostaphin anti-staphylococcal activity by lysozyme.

Authors: G Cisani; P E Varaldo; G Grazi; O Soro
Journal: Antimicrob Agents Chemother Date: 1982-04 Impact factor: 5.191